



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

October 15, 2024

Ilan Hadar
Chief Executive Officer
Silexion Therapeutics Corp
2 Ha'ma'ayan Street
Modi'in-Maccabim-Reut, Israel 7177871

Re: Silexion Therapeutics Corp
Registration Statement on Form S-1
Filed October 9, 2024
File No. 333-282556

Dear Ilan Hadar:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tamika Sheppard at 202-551-8346 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Jonathan M. Nathan